Escalier Biosciences
Somu is the Chairman of our board of directors. Somu is the co-founder and Managing Partner of New Science Ventures. Somu serves on the board of directors of Ralexar Therapeutics, Cambridge Epigenetix, Oxyrane, Resolve Therapeutics, Vascular Therapies, and Vaultive. Somu has also served on the board of directors of Dezima Pharma (acquired by Amgen), Ception Therapeutics (acquired by Cephalon), BioVex (acquired by Amgen), and Akarna Therapeutics (acquired by Allergan). Prior to founding New Science Ventures, Somu was a director at McKinsey & Company where he advised leading multinational companies in the pharmaceuticals, medical devices, biotechnology, photonics, software, and semiconductor industries. At McKinsey, Somu was the leader of the Strategy Practice, the Technology Practice, the Biotechnology Group, and the Healthcare Practice. He also served on the firm’s Investment Committee and led its Equity Portfolio Committee. Somu holds a B.Tech. degree from the Indian Institute of Technology and an M.B.A. from Harvard Business School.
This person is not in the org chart
This person is not in any teams
This person is not in any offices
Escalier Biosciences
Escalier Biosciences is developing both topical and oral RORγt inverse agonists for the treatment of a broad spectrum of psoriasis patients – from the underserved mild-to-moderate patients that would benefit from a safe and effective topical RORγt therapeutic to the more moderate-to-severe patients that would benefit from a safe and effective oral RORγt drug in lieu of injectable biologic therapies targeting IL-17 and IL-23.